1
|
Zhai LN, Zhao Y, Song XL, Qin TT, Zhang ZJ, Wang JZ, Sui CY, Zhang LL, Lv M, Hu LF, Zhou DS, Fang TY, Yang WH, Wang YC. Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax. Emerg Microbes Infect 2023; 12:2191741. [PMID: 36920800 PMCID: PMC10071900 DOI: 10.1080/22221751.2023.2191741] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Abstract
AbstractPulmonary anthrax is the most fatal clinical form of anthrax and currently available injectable vaccines do not provide adequate protection against it. Hence, next-generation vaccines that effectively induce immunity against pulmonary anthrax are urgently needed. In the present study, we prepared an attenuated and low protease activity Bacillus anthracis strain A16R-5.1 by deleting five of its extracellular protease activity-associated genes and its lef gene through the CRISPR-Cas9 genome editing system. This mutant strain was then used to formulate a lethal toxin (LeTx)-free culture supernatant extract (CSE) anthrax vaccine,of which half was protective antigen (PA). We generated liquid, powder, and powder reconstituted formulations that could be delivered by aerosolized intratracheal inoculation. All of them induced strong humoral, cellular, and mucosal immune responses. The vaccines also produced LeTx neutralizing antibodies and conferred full protection against the lethal aerosol challenges of B. anthracis Pasteur II spores in mice. Compared to the recombinant PA vaccine, the CSE anthrax vaccine with equal PA content provided superior immunoprotection against pulmonary anthrax. The preceding results suggest that the CSE anthrax vaccine developed herein is suitable and scalable for use in inhalational immunization against pulmonary anthrax.
Collapse
Affiliation(s)
- Li-Na Zhai
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.,State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Yue Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.,Basic medical college, Guizhou Medical University, Guizhou 550004, China
| | - Xiao-Lin Song
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Tong-Tong Qin
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Zhi-Jun Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Jia-Zhen Wang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Cheng-Yu Sui
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Li-Li Zhang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Meng Lv
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Ling-Fei Hu
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Dong-Sheng Zhou
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Tong-Yu Fang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Wen-Hui Yang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
| | - Yan-Chun Wang
- State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Biotechnology, Beijing 100071, China
| |
Collapse
|
2
|
Chavda VP, Vora LK, Apostolopoulos V. Inhalable Vaccines: Can They Help Control Pandemics? Vaccines (Basel) 2022; 10:vaccines10081309. [PMID: 36016197 PMCID: PMC9413847 DOI: 10.3390/vaccines10081309] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 08/09/2022] [Accepted: 08/11/2022] [Indexed: 12/15/2022] Open
Abstract
The emergence of a new coronavirus presents a huge risk to public health worldwide and has spread widely amongst the human population. Since its emergence, the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is frequently evolving by mutation and genetic recombination to give rise to new viral variants. These emerging variants pose a challenge to existing COVID-19 management strategies and vaccine efficacy. Interruption of viral spread is required as the merging variants pose higher transmissibility than the previous ones. To achieve this, local protection of the respiratory tract with immunity is essential. Here, we advocate the use of pulmonary/inhalable vaccines to achieve this goal.
Collapse
Affiliation(s)
- Vivek P. Chavda
- Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380009, Gujarat, India
- Correspondence: (V.P.C.); (V.A.)
| | - Lalitkumar K. Vora
- School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Vasso Apostolopoulos
- Immunology and Translational Research Group, Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
- Immunology Program, Australian Institute for Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia
- Correspondence: (V.P.C.); (V.A.)
| |
Collapse
|
3
|
Li B, Siuta M, Bright V, Koktysh D, Matlock BK, Dumas ME, Zhu M, Holt A, Stec D, Deng S, Savage PB, Joyce S, Pham W. Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine. Int J Nanomedicine 2016; 11:6103-6121. [PMID: 27895483 PMCID: PMC5117944 DOI: 10.2147/ijn.s112432] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The present study investigated the immunoenhancing property of our newly designed nanovaccine, that is, its ability to induce antigen-specific immunity. This study also evaluated the synergistic effect of a novel compound PBS-44, an α-galactosylceramide analog, in boosting the immune response induced by our nanovaccine. The nanovaccine was prepared by encapsulating ovalbumin (ova) and an adjuvant within the poly(lactic-co-glycolic acid) nanoparticles. Quantitative analysis of our study data showed that the encapsulated vaccine was physically and biologically stable; the core content of our nanovaccine was found to be released steadily and slowly, and nearly 90% of the core content was slowly released over the course of 25 days. The in vivo immunization studies exhibited that the nanovaccine induced stronger and longer immune responses compared to its soluble counterpart. Similarly, intranasal inhalation of the nanovaccine induced more robust antigen-specific CD8+ T cell response than intraperitoneal injection of nanovaccine.
Collapse
Affiliation(s)
- Bo Li
- Institute of Imaging Science, Vanderbilt University School of Medicine; Department of Radiology and Radiological Sciences
| | - Michael Siuta
- Institute of Imaging Science, Vanderbilt University School of Medicine
| | - Vanessa Bright
- Institute of Imaging Science, Vanderbilt University School of Medicine; Department of Radiology and Radiological Sciences
| | - Dmitry Koktysh
- Department of Chemistry, Vanderbilt University; Vanderbilt Institute of Nanoscale Science and Engineering
| | | | - Megan E Dumas
- Institute of Imaging Science, Vanderbilt University School of Medicine
| | - Meiying Zhu
- Institute of Imaging Science, Vanderbilt University School of Medicine
| | - Alex Holt
- Institute of Imaging Science, Vanderbilt University School of Medicine
| | - Donald Stec
- Department of Chemistry, Vanderbilt University; Vanderbilt Institute of Chemical Biology
| | - Shenglou Deng
- Department of Chemistry and Biochemistry, Brigham Young University
| | - Paul B Savage
- Department of Chemistry and Biochemistry, Brigham Young University
| | - Sebastian Joyce
- Department of Pathology, Microbiology and Immunology, Vanderbilt University; Veterans Administration Tennessee Valley Healthcare System
| | - Wellington Pham
- Institute of Imaging Science, Vanderbilt University School of Medicine; Department of Radiology and Radiological Sciences; Vanderbilt Institute of Chemical Biology; Department of Biomedical Engineering; Vanderbilt Ingram Cancer Center; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA
| |
Collapse
|